Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
By Jianjun Gao, Zhenxue Tian, Xu Yang. BioScience Trends, 2020
2,504 citations recorded by the source corpus.
The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.
Subfields: Infectious Diseases, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/909514b3ad22c37916ce577acb73c57cf6c558dc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study (2020, background): “In addition, chloroquine has demonstrated its efficacy in Chinese COVID-19 patients in clinical trials by reducing fever, improving CT imaging, and delaying disease progression [12] [13] [14] , leading Chinese experts to recommend chloroquine-based treatment (500 mg twice per day for ten days) as a ”
- Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence (2020, neutral): “Remdesivir is undergoing a large number of clinical trials in several hospitals, and the final efficacy of the drug is uncertain.”
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach (2020, neutral): “causes an impaired release of the virus from the endosome or lysosome and thus recommended to handle severe COVID-19 patients [120].”
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (2020, result): “A recent paper reported an inhibitor effect of remdesivir (a new antiviral drug) and chloroquine (an old antimalarial drug) on the growth of SARS-CoV-2 in vitro, [8] and an early clinical trial conducted in Chinese COVID-19 patients, showed that chloroquine had a significant effect, both in terms of”
- Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic (2020, neutral): “A number of SARS-related coronaviruses have been discovered in bats, and a working theory is that bats may have been the initial zoonotic host for SARS-CoV-2 given that its genome is 96.2% identical to a bat coronavirus (8).”
- Coronavirus disease 2019 (COVID-19) pandemic and pregnancy (2020, background): “However, it is worth noting that chloroquine is a drug with a large volume of distribution, and pharmacokinetic studies(53) have shown significantly lower plasma drug concentrations in pregnancy, which suggests the need for a higher dose in COVID-19 (at least 500 mg twice daily).(52) A relevant side”
- A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 (2020, neutral): “The authors also stated that these fi ndings came from “ more than 100 patients ” included in the trials [5].”
- The epidemiology, diagnosis and treatment of COVID-19 (2020, result): “The first results obtained from more than 100 patients showed the apparent efficacy of chloroquine in terms of reduction of exacerbation of pneumonia, duration of symptoms and delay of viral clearance, all in the absence of severe side effects [60] .”
- Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment (2020, background): “…recommended to take ribavirin and interferon drug because of the high risk for side effects but these drugs may be considered if treatment with lopinavir, ritonavir, chloroquine or hydroxychloroquine are ineffective (Chu et al., 2004; Gao et al., 2020; Huang et al., 2020; Y. H. Jin et al., 2020).”